Human PD-L1 Inhibitor Peptides

Programmed Death-Ligand (Immune Checkpoint Ligands)

  • Programmed death-ligand 1 (PD-1) serves as an important immunocheckpoint receptor that is actively studied in the context of clinical cancer immunotherapy1.

  • PD-L1, an important PD-1 ligand is widely expressed and is frequently overexpressed by tumor cells thereby limiting T cell activity and blocks antitumor immune responses1,2.

  • AnaSpec/EGT group offers readily available catalog PD-L1 inhibitor peptides for cancer immunotherapy research (blockade/inhibitor peptides against PD-1/PD-L1 interaction).

PD-L1 Inhibitor Peptides
PD-L1 Inhibitor I
PD-L1 Inhibitor II
PD-L1 Inhibitor III
PD-L1 Inhibitor IV
PD-L1 Inhibitor V

Immunomodulation Schemes

Anti-Cancer Immunosurveillance
  • Tumor antigens (on tumor cells) are recognized by Dendritic cells
  • Dendritic cells capture & present tumor antigens to T-cells
  • Activated T-cells bind to tumor cells
  • T-cells release cytokines & cause cell death
Immunosuppression via PD-L1
  • Tumor cells overexpress PD-L1.
  • PD-1 receptor expressed on activated T-cells binds to PD-L1 expressed on dendritic cells
  • T-cells get downregulated; cytokines production reduces
  • Tumor cell proliferates exhibiting immunotolerance

PD-L1 Inhibitor Peptides
AnaSpec/EGT Group offers peptide inhibitors (peptide ligands) that target human PD-1 (hPD-1). The peptide ligands contain sequences with key anchor residues that impact the binding of PD-L1 ligands to hPD-1.

Catalog # Product Sequence Size
AS-65581 Human PD-L1 Inhibitor I FNWDYSWKSERLKEAYDL 1 mg
AS-65582 Human PD-L1 Inhibitor II FNWDYSLEELREKAKYK 1 mg
AS-65583 Human PD-L1 Inhibitor III TEKDYRHGNIRMKLAYDL 1 mg
AS-65584 Human PD-L1 Inhibitor IV GNWDYNSQRAQLYNQ 1 mg
AS-65585 Human PD-L1 Inhibitor V LDYVNRRKMYQ 1 mg

Related Products

Cancer Research Peptides

1) Keir ME, et al. D-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309-14.
2) Li Q, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7(40):64967-64976.